New hope for hepatitis b: Real-World trial of pradefovir launches
NCT ID NCT07555340
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study looks at how well and how safely the drug pradefovir mesylate works for people with chronic hepatitis B. About 400 adults aged 18 to 65 with active hepatitis B will take the drug and be followed over time. The main goal is to see if the drug can lower the virus to undetectable levels, helping control the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.